Phase 2 Pulmonary Hypertension Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to sign a consent form and follow all study procedures for the full duration of the trial
• People who have been confirmed to have pulmonary hypertension (high blood pressure in the lungs) caused by a chronic lung disease, based on a specific heart-lung pressure test called a right heart catheterisation (RHC), with results showing: average lung artery pressure above 20 mmHg, lung artery wedge pressure of 15 mmHg or below, and lung vascular resistance above 2 Wood units
• People whose pulmonary hypertension is classified as "Group 3" — meaning it is linked to lung disease and/or low oxygen levels
• People who are already taking approved pulmonary hypertension medications and have been on a stable dose for at least 30 days
• People who are able to swallow oral (tablet/capsule) medication and are willing to follow the study medication schedule
• Women who could become pregnant must agree to use highly effective contraception during the study and for 4 weeks after it ends
• Men who could father a child must agree to use condoms or other effective contraception with their partner during the study
• People who are willing to fast (no food or caloric drinks) for 6 hours before each clinic visit

Who may not be able to join:

• People who have had Type 1 or Type 2 diabetes at any point in the past year
• People who have had episodes of dangerously low blood sugar (with symptoms) in the 90 days before enrolling
• People who have used diabetes medications — including pioglitazone, rosiglitazone, metformin, or insulin — in the 90 days before enrolling
• People with a history of left-sided heart failure (either type: reduced pumping or stiffening of the heart)
• People whose pulmonary hypertension is caused by left heart disease (classified as "Group 2" pulmonary hypertension)
• People with a past or current history of bladder cancer
• People who have had a low platelet count (a blood clotting cell count of 120 or below, or a diagnosis of thrombocytopenia) in the 90 days before enrolling, or whose platelet count is found to be low during the screening or enrolment process
• People who have cystic fibrosis
• People who are currently pregnant or breastfeeding
• People who currently use tobacco products
• People who have had an allergic reaction to pioglitazone or any of its ingredients
• People who have taken part in another clinical drug trial within the past 30 days

Important: Always verify eligibility with the trial site directly before applying.